A novel drug, baxdrostat, has produced impressive findings in reducing resistant elevated blood pressure and safeguarding kidney function. During the FigHTN Phase 2 trial, patients with chronic kidney disease (CKD) and uncontrolled blood pressure had approximately a 5% reduction in systolic blood pressure when treated with baxdrostat added to background therapy.
More impressively, it cut urinary albumin loss by 55%, a chief indicator of heart and kidney disease. That implies that baxdrostat might retard kidney damage and benefit long-term patient health outcomes.
Though still in research, specialists think that this drug could revolutionize treatment for patients who, despite treatment, have persistently high blood pressure.
Would you trust a new drug if it promised better kidney protection along with BP control?
MBH/PS